Main content

    ALS / Neuromuscular Disorders
    Clinical Trials

    The Forbes Norris MDA/ALS Research Center

    Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Amyotrophic Lateral Sclerosis (ALS)  |  Primary lateral sclerosis (PLS)


    Active Trials

    Amyotrophic Lateral Sclerosis (ALS)

    Title: A study to explore the safety and tolerability of Acthar in patients with Amyotrophic Lateral Sclerosis
    Description: The purpose of this study is to investigate the safety and tolerability of 4 different doses of Acthar in ALS patients
    Investigator: Jonathan Katz, MD

    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have had symptoms for less than 3 years
    Status: Active and open to enrollment

    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study Acthar

    Title: Multi-center, randomized controlled study of the NeuRx® Diaphragm Pacing System™ in participants with Amyotrophic Lateral Sclerosis (ALS)
    Description: The purpose of this study is to see whether electrical stimulation of the diaphragm (the main breathing muscle at the bottom of your chest) with the NeuRx® Diaphragm Pacing System™ benefits people with ALS
    Investigator: Jonathan Katz, MD

    Eligibility: 
Subjects with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have moderate diaphragm weakness
    Status: Active and open to enrollment

    Contact: Dallas Forshew, RN, 415-600-3938, Email: ForsheD@cpmcri.org about Study NeuRx DPS Randomized Controlled Trial

    Title: A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Efficacy Of CK-2017357 In Patients With Amyotrophic Lateral Sclerosis (ALS)
    Description: The purpose of this research study is to evaluate the safety and effectiveness of CK-2017357 in patients with ALS
    Investigator: Jonathan Katz, MD

    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease moderate hand grip weakness.
    Status: Active and open to enrollment

    Contact: Marguerite Engel, 415-600-3758, Email: EngelM@cpmcri.org about Study CK-2017357

    Title: A Multi-Center Controlled Screening Trial of Rasagiline in Subjects with Amyotrophic Lateral Sclerosis (ALS)
    Description: The purpose of this Phase II research study is to evaluate the safety and effectiveness of Rasagiline in patients with ALS
    Investigator: Jonathan Katz, MD

    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have had symptoms for less than 24 months

    Status: Active and open to enrollment

    Contact: Marguerite Engel, 415-600-3758, Email: EngelM@cpmcri.org about Study Rasagline

    Title: Average Volume Assured Pressure Support (AVAPS) in ALS Patients with Early Respiratory Insufficiency: A Randomized Crossover Trial
    Description: The purpose of the study is to test two different types of nighttime assisted breathing with a BiPAP machine. We are trying to find out if it matters how the breath is delivered by the machine (pressure or volume). The questions we are trying to answer is if one method or the other makes the user more comfortable and if one makes you feel better at night and during the day.
    Investigator: Jonathan Katz, MD
    Eligibility: Subjects with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have some early breathing changes that qualify them for nighttime use of a BiPAP machine
    Status: Active and open to enrollment
    Contact: Giovanna Kushner, 415-600-3983, Email: KushneG@cpmcri.org about Study AVAPS

    Title: Multicenter ALS Cohort of Oxidative Stress and Disease Progression
    Description: The first purpose of this observational study is to collect information to help identify if certain factors affect the rate that the disease worsens (disease progression). This information may also give clues to the underlying cause of the disease.
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have had symptoms for less than 18 months
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study ALS Cohort

    Title: The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis
    Description: The purpose of this study is to find out if Nuedexta® will improve the bulbar functions in people with ALS. Bulbar functions include speech, swallowing, and the production of saliva (salivation)
    Investigator: Jonathan Katz, MD
    Eligibility: Subjects with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease and who have difficulty speaking and/or swallowing
    Status: Active and open to enrollment
    Contact: Marguerite Engel, 415-600-3758, Email: EngelM@cpmcri.org about Study Bulbar Treatment

    Title: HDE Post-Approval Study (PAS) of NeuRx DPS TM (Diaphragm Pacing System) for ALS
    Description: The purpose of this research study is to collect more information about the possible risks and benefits of the NeuRx DPS TM device (Diaphragm Pacing System)
    Investigator: Jonathan Katz, MD
    Eligibility: Subjects with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have moderate diaphragm weakness
    Status: Active and open to enrollment
    Contact: Dallas Forshew, RN, 415-600-3938, Email: ForsheD@cpmcri.org about Study NeuRx DPS

    Back to top

    Primary lateral sclerosis (PLS)

    Title: Multicenter PLS Cohort Study of Oxidative Stress and Disease Progression
    Description: The first purpose of this observational study is to collect information to help identify if certain factors affect the rate that the disease worsens (disease progression). This information may also give clues to the underlying cause of the disease.
    Investigator: Jonathan Katz, MD
    Eligibility: Subjects with a diagnosis of clinically definate primary lateral sclerosis (PLS) who have had symptoms for at least 5 years but not greater than 15 years
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study PLS Cohort

    • updated August 2013

    Back to top